SPOTLIGHT: Vasella defends dual role at Novartis

Novartis Chairman and CEO Daniel Vasella (photo) got a bit defensive at his company's annual meeting yesterday. Questioned about his pulling double duty as chairman and CEO, Vasella countered that firms with one person in each slot spend too much time and money settling conflicts between the two. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.